

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claims 1-4 (Canceled)

5. (New) A method of treating an inflammatory disease in a mammal, which comprises administering to the mammal monovalent antibody fragments directed against Fc α RI receptor.

6. (New) The method of claim 5, wherein the monovalent antibody fragments are directed against EC2 domain of the Fc α RI receptor.

7. (New) The method of claim 5, wherein the inflammatory disease is selected from the group consisting of lupus, rheumatoid arthritis, diabetes, nephritis interstitial renal fibrosis, obstructive nephropathy and gut inflammatory disorders.

8. (New) The method of claim 5, wherein the inflammatory disease is an allergy.

9. (New) The method of claim 8, wherein the allergy is asthma.

10. (New) The method of claim 5, whereby IgG-induced phagocytosis is inhibited.

11. (New) The method of claim 10, whereby IgE-mediated exocytosis is further inhibited.

12. (New) The method of claim 9, whereby antigen-induced bronchial hyper-reactivity is prevented.

Attorney Docket No.: 70078.

13. (New) The method of claim 5, wherein the monovalent antibody fragments are administered in a form of a composition.

14. (New) The method of claim 13, wherein the composition is administered by injection.

15. (New) The method of claim 14, wherein the injection is intramuscular, intradermal, intravenous, intraperitoneal or subcutaneous.

16. (New) The method of claim 13, wherein the composition is administered by aerosol.

17. (New) The method of claim 5, wherein the mammal is human.

18. (New) The method of claim 5, wherein the antibody fragments are Fab fragments of an anti-Fc α RI mAb.

19. (New) The method of claim 18, wherein the anti-Fc α RI mAb is (IgG1k, clone A 77).

20. (New) A pharmaceutical composition, comprising:

- a) monovalent antibody fragments directed against mammalian Fc α RI receptor, and
- b) a carrier.

21. (New) The pharmaceutical composition of claim 20, in a form suitable for injection.

22. (New) The pharmaceutical composition of claim 20, in a form suitable for inhalation.

Attorney Docket No.: 70078.

23. (New) The pharmaceutical composition of claim 20, wherein the monovalent antibody fragments are directed against EC2 domain of the Fc α RI receptor.

24. (New) The pharmaceutical composition of claim 20, wherein the antibody fragments of an anti-Fc α RI mAb.

25. (New) The pharmaceutical composition of claim 24, wherein the anti-Fc α RI mAb is (IgG1k, clone A 77).